U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to 46,316.07.These are the top stocks that gained the attention of retail traders and investors throughout the day.Wolfspeed Inc. (NYSE: WOLF)Wolfspeed’s stock skyrocketed by 1,726.45%, closing at $22.10, with an intraday high and low of $22.10 and $8.05, respectively. The stock reached a 52-week high of $22.10 and ...

CANADA - 2025/06/03: In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMoonLake Immunotherapeutics (NASDAQ: MLTX), a biopharmaceutical firm in the clinical stage, experienced substantial fluctuations last week. The stock climbed 10% on Friday, September 26, as investors expected favorable outcomes from Phase 3 trials of son ...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst consensus estimate of $5.310 million.Inventiva shares dipped 5.5% to $5.72 in pre-market trading.Here ar ...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst consensus estimate of $5.310 million.Inventiva shares dipped 5.5% to $5.72 in pre-market trading.Here ar ...

并购交易 - Genmab计划以80亿美元全现金收购Merus NV 旨在将其突破性疗法Petosemtamab纳入后期研发管线[1] - 受收购消息影响 Merus NV股价在盘前交易中大幅上涨38.2%至95.21美元[1] 盘前股价显著上涨公司 - Steakholder Foods Ltd – ADR股价上涨92%至8.32美元 原因系公司签署了收购Twine Solutions的协议[4] - JFB Construction Holdings股价飙升77.4%至12.15美元 此前公司宣布完成4400万美元的私募配售[4] - Plus Therapeutics Inc股价上涨24.3%至0.77美元 公司与UnitedHealthcare就用于转移性中枢神经系统癌症的CNSide脑脊液检测试剂达成全国覆盖协议[4] - Enanta Pharmaceuticals Inc股价上涨22.7%至9.69美元 公司将于周一公布其用于高危成人RSV的Zelicapavir的2b期研究顶线结果[4] - Tilray Brands Inc股价大涨17.4%至1.35美元 公司计划于10月9日公布第一季度财务业绩[4] - Larimar Therapeutics Inc股价上涨16.4%至5.93美元 公司将于9月2日电话会议及网络直播中发布针对弗里德赖希共济失调的Nomlabofusp项目更新[4] 盘前股价显著下跌公司 - MoonLake Immunotherapeutics股价暴跌86.3%至8.50美元 尽管其3期VELA试验显示Sonelokimab在中度至重度化脓性汗腺炎中达到统计学上显著的HiSCR75应答[4] - Maris Tech Ltd股价下跌37.3%至2.62美元 公司公布上半年每股亏损0.30美元[4] - Sunrise New Energy Co Ltd股价下跌28.1%至0.88美元 此前公司宣布计划建设1GW美国锂电池组项目[4] - Youxin Technology Ltd股价下跌13.9%至0.058美元 公司宣布进行1比80的并股以重新符合纳斯达克上市规定 将于9月30日生效[4] - Top KingWin Ltd股价下跌12.8%至4.07美元 此前公司宣布与Walker Times International签订销售合同 出售10,000台TK-D2C AI机器人[4] - Quantum-Si Inc股价下跌10.1%至1.34美元 公司提交了高达3亿美元的混合储架发行申请[4]

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 21, Leerink Partners analyst Thomas Smith reiterated a Buy rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a price target of $73. Smith highlighted the potential of the company’s Sonelokimab in treating moderate-to-severe hidradenitis suppurativa. He noted that the upcoming Phase 3 VELA trial results to be a key catalyst for the stock and believes that it will show ...

ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2025. Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: "Q2 has been another strong quarter for MoonLake. We narrowed guidance for the timing of the primary endpoint readout for our pivotal Phas ...

文章核心观点 - 该文章由Biotech Analysis Central制药服务负责人Terry Chrisomalis撰写，旨在推广其付费订阅服务[1] - 服务提供对多家制药公司的深度分析，月费49美元，年费399美元可享受33.5%折扣[1] - 该投资小组拥有600多篇生物技术投资文章，10多只中小盘股票模型组合及实时聊天等功能[2] 服务内容 - 提供制药公司深度分析服务，涵盖行业研究和个股研究[1] - 投资小组包含600+生物技术投资文章库，形成系统化研究资源[2] - 建立10+中小盘股票模型组合，每只股票配备深度分析报告[2] - 提供实时聊天功能和分析报告，协助医疗健康领域投资者决策[2] 商业模式 - 采用订阅制收费，月费标准定价49美元[1] - 年费模式定价399美元，较月费模式节省33.5%[1] - 目前提供两周免费试用期吸引用户[1]